steatohepatitis. 12 Moreover, IL-1Ra was associated with arterial stiffness, 13 cardiovascular mortality, 14 and with adverse changes in insulin sensitivity and with total mortality. 15 Surviving patients in an intensive care unit (ICU) had very high IL-1Ra levels in plasma, but the non-survivors had lower levels of IL-1Ra. 16 Although IL-1Ra is an anti-inflammatory cytokine, it increases rapidly enough even for robust clinical measurements.
Only limited and contradictory data are available on the prognostic role of IL-1Ra in haematological patients with febrile neutropenia. 17 We postulated that IL1-Ra might function as an early biomarker for complicated course of febrile neutropenia after intensive chemotherapy in patients with haematological malignancies, and compared its predictive capacity to that of conventional biomarkers.
| PATIENTS AND ME THODS

| Patients
The study population consisted of adult in-patients at the adult haematology ward of Kuopio University Hospital between November 2009 and November 2012. The study included 86 patients with febrile neutropenia after intensive chemotherapy. The baseline characteristics are expressed in Table 1 . All the patients included in the study gave their written informed consent.
Development of febrile neutropenia, severe sepsis and septic shock were registered prospectively. Blood samples were collected at the onset of fever (day 0), and on the two following mornings (day 1 and day 2). The patients were carefully monitored until recovery of neutropenia (median 7 days, range 4-35 days), and daily examined for possible signs of severe sepsis. The time from the start of the fever to the possible development of severe sepsis was registered.
Blood pressure, heart rate, body temperature, oxygen saturation and respiratory frequency were monitored by the nursing staff at the haematological ward.
The initial empirical antibiotic therapy for febrile neutropenia included a combination of intravenous ceftriaxone and tobramycin. New blood cultures were taken if the fever persisted for 3-5 days.
In the case of prolonged fever, caspofungin was combined to empirically cover a possible fungal infection. Mucosal symptoms and signs of fungal infection were treated with oral fluconazole.
Trimethoprim-sulfamethoxazole was used as Pneumocystis jiroveci prophylaxis for four months after ASCT. Non-Hodgkin lymphoma patients (NHL) receiving ASCT were treated with oral ciprofloxacin as a part of the clinical protocol (500 mg bid starting two days before ASCT). The prophylaxis continued until the recovery of neutropenia or introduction of focus-guided antimicrobial treatment.
Febrile neutropenia was defined applying the criteria from Infectious Diseases Society of America. 18 Neutropenia was defined as a neutrophil count <0.5 × 10 9 /L or a predicted decrease to less than 0.5 × 10 9 /L. Fever was defined as a single oral temperature of 38.3°C or higher, or a temperature of 38.0°C or higher for at least 1 hour.
Sepsis and septic shock were defined according to the guidelines of the American College of Chest Physicians Consensus, valid during the study entry. 19 Sepsis was defined as a syndrome in which systemic inflammatory response is present with infection diagnosed clinically or microbiologically, valid at the time of the inclusion of study patients. Septic shock was defined as a subtype of sepsis, if hypoperfusion (systolic arterial pressure was <90 mmHg, a mean arterial pressure <60 mmHg or a reduction in systolic blood pressure of <40 mmHg from baseline) was present despite adequate volume resuscitation in the absence of other causes of hypotension. Severe sepsis was defined as a subset of sepsis with sepsis-induced organ dysfunction. 19 The primary endpoint of the study was the development of severe sepsis. The secondary endpoint was the complicated course of febrile neutropenia with blood culture positivity, septic shock or death for sepsis.
| Methods
Blood cultures were processed using the automated blood culture system Bactec 9240 (Becton Dickinson, Sparks, MD, USA). The incubation episode was 7 days for both aerobic and anaerobic bottle and 42 days for MYCO F/Lytic bottles.
Blood samples for IL1-Ra, C-reactive protein (CRP) and procalcitonin (PCT) were collected at the onset of febrile neutropenia (d0) and in the following next two mornings (d1 and d2). Serum was separated and samples were stored frozen at −70°C until analysed. 
| Statistical analysis
Data operating characteristic curve (ROC) analysis was carried out to evaluate the prognostic ability of IL-1Ra, PCT and CRP, providing values for the area under the curve (AUC) with 95% confidence intervals (CI). The significance of differences between the AUCs for each day was tested according to Hanley and McNeil. 20 Sensitivity, specificity, positive and negative predictive value were defined for each variable on each day. Youden's indices (sensitivity + specificity − 1) were used when defining the optimal cut-off value for IL-1Ra, PCT and CRP on each study day from day 0 to day 2. The confidence intervals for
Youden's indicis were calculated according to Shan. 21 Youden's index was also used in the comparison of diagnostic properties of IL-1Ra, PCT and CRP. A P-value of less than 0.05 was considered significant.
.4 | Ethical approval
This study is conducted according to the principles expressed in the Declaration of Helsinki and was approved by Ethical Board of North Savo Hospital District (100/2006).
| RE SULTS
Of the 86 patients with febrile neutropenia, 18 patients (21%) had a positive blood culture finding. Gram-negative bacteraemia was found in three patients (17% out of all positive blood culture findings) and Eight patients (9%) developed severe sepsis with signs of organ failure and three patients developed septic shock (3%). Among the patients with severe sepsis (n = 8), altogether six patients had a microbiologically proven infection. Their blood culture findings included Pseudomonas aeruginosa (n = 1), Enterococcus faecium (n = 3),
Streptococcus mitis (n = 1) and Staphylococcus epidermidis (n = 1). In two patients with severe sepsis, the blood cultures remained negative. Of these patients, all those with septic shock (n = 3) had a microbiologically proven infection. Their blood culture findings included
Enterococcus faecium (n = 2) and Pseudomonas aeruginosa (n = 1).
Three patients died, one due to respiratory syncytial virus pneumonia and respiratory failure on d10 (IL-1Ra 504-545-573 ng/L from d0 to d2), one due to severe sepsis on d2 (IL-1Ra 5151-20000 ng/L from d0 to d1) and one due to septic complications on d12 (IL-1Ra
1070-922-908 ng/L from d0 to d2). The median time from the start of the fever to the development of severe sepsis or septic shock was three days.
The results of the correlation analysis between IL-1Ra, CRP and
PCT from d0 to d2 are shown in Table S1 . Statistically significant correlations were encountered between IL-1Ra and PCT on each day.
On d0 and d1, the correlations between IL-1Ra with next day PCT were high, highest between IL-1Ra d1 with PCT d2. The highest correlation between IL-1Ra and CRP was observed between d1 IL-1Ra and d2 CRP. Overall, an earlier day IL-1Ra seems to correlate best with a later day PCT or CRP.
Results from the ROC curve analysis from d0 to d2 for IL-1Ra, CRP and PCT to predict severe sepsis are shown in Table 2 . IL-1Ra
was the only of the three biomarkers with a statistically significant McNeil method, the differences did not quite reach statistical significance (Table S2 ).
The results from the ROC curve analysis from d0 to d2 for IL-1Ra, CRP and PCT to predict blood culture positivity or severe sepsis (including septic shock or death from sepsis) are shown in Table S3 . IL-1Ra showed highest absolute AUC value on d0 (AUC: 0.71, 95% CI: 0.59-0.83, P = 0.005), remaining statistically significant on d1.
The diagnostic characteristics including sensitivity, specificity, positive and negative predictive values for IL-1Ra, CRP and PCT to predict severe sepsis on d0-d2 from the onset of febrile neutropenia are presented in Table 3 . The means with standard errors according to the development of severe sepsis are depicted in Figure 2 . It shows the peak value of IL-1Ra on d1, whereas the rise of CRP and PCT was less rapid.
Medians (IQRs) of IL1-Ra, CRP and PCT were compared by the development of severe sepsis (Table S4 ). The patients developing severe sepsis had higher IL-1Ra levels than those without it on d0 and on d1. The d1 IL1-Ra median (IQR) was 3064 (552-9301) ng/L in severe sepsis compared to 256 (198-470) ng/L in patients without it.
Significant differences according to the presence of severe sepsis were observed in the level of CRP on d1, and of PCT on d1 and d2.
Of note, IL-1Ra was the only of these three markers that showed an early difference already on d0 between the patients with and without severe sepsis. Statistically significant differences (higher IL-1Ra levels) were also observed in patients with positive vs. negative blood culture findings on d0 and d1 (Table 4 ). Respective differences in the levels of PCT were observed on d0, on d1 and on d2. As to CRP, the only slight statistically significant difference was observed on d1 (P = 0.039).
In the small group (n = 3) of patients who developed septic shock IL-1Ra levels were higher in comparison with the patients without 
| D ISCUSS I ON
Our study group has previously investigated several biomarkers for predicting the development of febrile neutropenia to sepsis, but so far none of them has been accepted in routine clinical use apart from PCT and CRP. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Rapid diagnostic tools are needed to single out patients at highest risk for complications at the first hours and days of febrile neutropenia. In this prospective study, IL-1Ra was found to be a prompt biomarker in haematological patients with febrile neutropenia after intensive chemotherapy. It predicts the development of severe sepsis earlier than CRP or PCT. Its diagnostic capacity was best on d1 from the start of fever, and it showed predictiveness already on d0.
CRP is widely used to indicate infection. However, at the early stages, it reacts too slowly for prognostic use. 22 An earlier study on patients with febrile neutropenia showed that CRP rises within 48-72 hours in neutropenic infection. 32 Significant increase was observed on day 2 in patients who developed demonstrable infection such as bacterial or fungal infection with or without positive blood culture findings. This is in agreement with our results showing that the increase of CRP is quite slow and not observed until on day 2 F I G U R E 2 Means (standard error of mean) of interleukin-1 receptor antagonist (IL-1Ra) (A), C-reactive protein (CRP) (B) and procalcitonin (PCT) (C) on day 0 (d0), day 1 (d1) and day 2 (d2) from the start of febrile neutropenia according to the presence of severe sepsis. Severe sepsis-dashed line; no severe sepsis-solid line [Colour figure can be viewed at wileyonlinelibrary.com] from the start of febrile neutropenia, suggesting that the role of CRP as an early prognostic marker in this patient population is doubtful.
Furthermore, it is non-specific for bacterial infections, mainly because of its capacity to increase also in other conditions such as tissue damage. 33 PCT seems to be useful in the differentiation of sepsis from non-infectious causes in febrile neutropenia. 34 To detect bacteraemia, culture methods are needed, but they are time-consuming and often give false-negative results or the results may only indicate microbial contamination. 35 As in most previous studies, in the present study, PCT had a better diagnostic capacity than CRP to predict complicated course of febrile neutropenia. 29, 36 Meidani et al 36 compared PCT and CRP in febrile neutropenic patients with haematological malignancies.
Sensitivity and specificity in ROC curve analysis for patients who developed sepsis was higher for PCT (92.5% and 97.3%, respectively).
In our study, an early peak in the concentration of PCT was not as distinct as in that of IL-1Ra in patients with febrile neutropenia and severe sepsis.
In 2004, a new biomarker sCD14-subtype (presepsin) was found.
In several studies, presepsin seems to have a better sensitivity and specificity in the early diagnosis of sepsis compared to other markers, such as CRP and PCT. 37 It is also suitable for assessment of the severity and the prognosis of sepsis. 38 However, presepsin levels are affected by other conditions such as kidney dysfunction. 39 The source of presepsin, CD14, a cell surface glycoprotein is expressed in innate immune response cells. 40 It is unclear how neutropenia affects the level of presepsin, and there are only a few studies concerning presepsin as a biomarker for sepsis in patients with febrile neutropenia. So far the results have not been encouraging for clinical use. 41, 42 Not even the current guidelines 43 for clinical criteria of sepsis have helped to recognise patients with febrile neutropenia at risk for high mortality. 44 In our previous study, the Quick Sequential Organ Failure Assessment (qSOFA) scoring showed very low sensitivity, as only one of eight patients developing severe sepsis received 3 quick SOFA points predicting high risk for in-hospital mortality. 28 The focus of the study was in observing even a slight change towards septic haemodynamics or multiple organ failure. The patient care took place at a haematological ward, not in an intensive care unit, and the treatment protocol was proactive, aiming at early recognition of sepsis by screening potentially septic patients who may benefit from early intervention. Therefore, we chose to keep in old definition for sepsis possibly with a better sensitivity but less specificity.
Although therapeutic use of IL1-Ra (anakinra) has been adopted in treating autoimmune rheumatoid arthritis, 45 20 Furthermore, when comparing the Youden's indices between IL-1Ra, CRP and PCT on d0-d1 for severe sepsis, IL-1Ra had the highest absolute values but the confidence intervals were crossing. However, in comparison with the other two biomarkers, the predictive ability of IL-1Ra was systematically highest on d0-d1, which is of major clinical importance.
Polymorphism of IL-1 receptor antagonist gene was not measured.
Such polymorphism has been suggested to influence not only the levels of plasma IL1-Ra, but also to the survival from severe sepsis or septic shock. 50 Analysis on gene polymorphism of IL1-Ra and other central molecules of the innate immunity would expand the perspective of the biology of neutropenic sepsis.
In conclusion, close monitoring and early initiation of therapy are imperative in reducing morbidity and mortality of febrile neutropenic haematological patients at risk for severe sepsis. A biomarker recognising complication early enough has been sought intensively. The requirements of such a biomarker include not only good diagnostic
properties, but also a suitable time-frame for clinical purposes. In febrile neutropenia, IL-1Ra is a potential biomarker for severe sepsis fulfilling both of these requirements and could therefore help to select those septic patients who benefit from early intensified treatment. Further and larger studies would be helpful to confirm these findings.
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